CD36 and neoplasm: Following intervention with the cholesterol inhibitor MβCD, the expression of cholesterol synthesis-related proteins (CD36, SREBP2 and HMGCR) decreased, while the expression of cholesterol efflux-related proteins (APOA1 and ABCG1) increased, leading to significant inhibition of tumor cell growth.